在肝细胞癌中测序系统疗法
Ben Ponvilawan1, Marc T Roth2,3
1Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Current treatment options in oncology
|October 16, 2023
概括
免疫检查点抑制剂 (ICI) 疗法在不可切除的肝细胞癌 (HCC) 中比索拉费尼布更受青,提供更高的生存率. 阿特佐利祖马布加贝瓦齐祖马布和杜尔瓦卢马布加特梅利卢马布是最好的选择,其他环境和生物标志物的研究正在进行中.
科学领域:
- 肝细胞癌治疗方法 肝细胞癌治疗方法
- 在瘤学中的免疫疗法.
- 胃肠病学和肝病学 胃肠学和肝病学
背景情况:
- 无法切除的肝细胞癌 (HCC) 有多种已批准的治疗选择.
- 含有免疫检查点抑制剂 (ICI) 的疗法在一线HCC治疗中,与索拉芬尼相比,具有更高的整体存活率 (OS),特别是在与肝炎病毒相关的病例中.
研究的目的:
- 对不可切除的肝细胞癌 (HCC) 的现有和新兴治疗策略进行审查.
- 讨论免疫检查点抑制剂 (ICI) 和氨酸激酶抑制剂 (TKI) 在各种HCC环境中的作用.
- 突出HCC管理中的挑战和未来方向.
主要方法:
- 对HCC治疗的当前文献和临床试验数据的审查.
- 分析一线和后一线治疗选择,包括ICI和TKI.
- 讨论生物标志物和HCC治疗中的未来研究方向.
主要成果:
- 含有ICI的疗法,特别是阿特佐利祖马布加贝瓦齐祖马布和杜尔瓦卢马布加特梅利卢马布,是不可切除的HCC的首线治疗方案,除非禁忌.
- 索拉费尼布仍然是选择儿童-皮格BHCC患者的关键选择,阿特佐利祖马布加贝瓦西祖马布正在调查中.
- 在移植后的复发和后期的设置中,TKIs显示出潜在的潜力,而ICI反应的生物标志物的实用性是不一致的.
结论:
- 无法切除的HCC的第一线治疗应优先考虑含ICI的疗法,因为OS优越.
- 需要进一步的研究,以优化后期治疗,生物标志物使用和ICI安全性在特定的HCC群体,如移植后复发.
- 个性化治疗策略,可能包括TKI和遗传突变分析,对于推进HCC护理至关重要.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.9K
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.4K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Hepatic Portal System
1.4K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
1.4K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
